Autolus Therapeutics (AUTL) EBIT Margin (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly EBIT Margin came in at 298.35% in Q4 2025, up 26130165.0% YoY from N/an in Q4 2024, and up 11.71% on a QoQ basis from 337.93% in Q3 2025.
Autolus Therapeutics (AUTL) EBIT Margin (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of EBIT Margin data on file, last reported at 298.35% in Q4 2025.
- Quarterly EBIT Margin rose 26130165.0% year-over-year to 298.35% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 358.87% (up 202464.0% YoY) and the FY2025 annual result came in at 358.87%, up 202676.0% from the prior year.
- EBIT Margin climbed to 298.35% in Q4 2025, from 337.93% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 292.58% in Q2 2025 to a low of 261600.0% in Q4 2024.
- A 5-year average of 23953.96% and a median of 2039.84% in 2021 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin sank 899125 bps — and 2025, when it soared 26130165 bps.
- Tracing AUTL's EBIT Margin over 5 years: stood at 17099.58% in 2021, then soared by 98 bps to 318.39% in 2022, then plunged by 3219 bps to 10567.73% in 2023, then tumbled by 2375 bps to 261600.0% in 2024, then jumped by 100 bps to 298.35% in 2025.
- The last three EBIT Margin figures came in at 298.35% (Q4 2025), 337.93% (Q3 2025), and 292.58% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | -95.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.95% |
| Dec 31, 2025 | -298.35% |
| Sep 30, 2025 | -337.93% |
| Jun 30, 2025 | -292.58% |
| Mar 31, 2025 | -726.34% |
| Dec 31, 2024 | -261,600.00% |
| Mar 31, 2024 | -383.73% |
| Sep 30, 2023 | -10,567.73% |
| Mar 31, 2023 | -3,030.03% |
| Dec 31, 2022 | -318.39% |
| Sep 30, 2022 | -1,576.49% |
| Mar 31, 2022 | -21,798.80% |
| Sep 30, 2021 | -17,099.58% |
| Jun 30, 2021 | -2,503.19% |
| Mar 31, 2021 | -14,822.30% |
| Dec 31, 2020 | -11,715.35% |
| Sep 30, 2020 | -9,750.68% |
| Jun 30, 2020 | -13,496.25% |
| Mar 31, 2020 | -11,409.17% |
| Jun 30, 2019 | -2,926.24% |